Dramatic inhibition of amiodarone metabolism induced by grapefruit juice

British Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2000, Pages 373-378

  Libersa, Christian C ^a,b,c   Brique, Serge A ^b   Motte, Kokou B ^a   Caron, Jacques F ^a   Guédon Moreau, Laurence M ^a   Humbert, Luc ^b   Vincent, A ^a   Devos, Patrick ^b   Lhermitte, Michel A ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c University of Lille   (France)

Author keywords

Amiodarone; Grapefruit juice; Interaction; Metabolism; Pharmacokinetics

Indexed keywords

AMIODARONE; CYTOCHROME P450 3A; DEETHYLAMIODARONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CITRUS FRUIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL;

EID: 0034072565     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00163.x     Document Type: Article

References (45)

1. 1 Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 1970; 39: 657-667.
2. 2 Young RA, Mehendale HM. In vitro metabolism of amiodarone by rabbit and rat liver and small intestine. Drug Metab Dispos 1986; 14: 423-429.
3. 3 Flanagan RJ, Storey GCA, Holt DW, Farmer PB. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol 1982; 34: 638-643.
4. 4 Zipes DP, Pristowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol 1984; 3: 1059-1071.
5. 5 Harris L, McKenna W, Rowland DE, et al. Plasma amiodarone and desethylamiodarone levels in chronic oral therapy. Circulation 1981; 64(SupplIV): 263.
6. 6 Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840-847.
7. 7 Marchiset D, Bruno R, Djiane P, et al. Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm Drug Dispos 1985; 6: 209-215.
8. 8 Fruncillo RJ, Bernhard R, Swanson BN, Vlasses PH, Fergusson RK. Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in rat. J Pharm Pharmacol 1985; 37: 729-731.
9. 9 Trivier JM, Libersa C, Belloc C, Lhermitte M. Amiodarone N-desethylamiodarone in human liver microsomes: involvement of cytochrome P450, 3A enzymes (first report). Life Sci 1993; 52: PL91-96.
10. 10 Fabre G, Julian B, Saint-Auber B, Joyeux H, Berger Y. Evidence of CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21: 978-985.
11. 11 Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
12. 12 Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955-956.
13. 13 Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporin in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-459.
14. 14 Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F. In vitro inhibition of midazolain and quinidine metabolism by flavonoids. Eur J Clin Pharmacol 1995; 48: 367-371.
15. 15 Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailibility and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36: 345-351.
16. 16 Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103-121.
17. 17 Runkel M, Bourian M, Tegmeier M. et al. The role of naringin in the interaction of drugs with juices or grapefruit juices [abstract]. Naunyn Schmiedeberg's Arch Pharmacol 1997; 355(Suppl 4): R123.
18. 18 Talajic M, DeRodde MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 1987; 75: 265-271.
19. 19 Zhou L, Chen BP, Klugger J, Fan C, Chow MS. Effects of amiodarone and its metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31: 1672-1678.
20. 20 Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988; 36: 121-131.
21. 21 Tieleman RG, Gosselink AT, Crijns HJ, Van-Gelder IC, Van-Berg MP, DeKam PJ. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53-57.
22. 22 Plomp TA, Hauer RNW, Robles de Medina EO. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgically treated patients on long-term oral amiodarone treatment. In Vivo 1990; 4: 97-100.
23. 23 Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996; 78(Suppl 4A): 41-53.
24. 24 Physician's Desk Reference. Montvale: Medical Economics Company 1997.
25. 25 Bazett HC. An analysis of the times relations of electrocardiograms. Heart 1920; 7: 353-370.
26. 26 Trivier JM, Pomery J, Libersa C, Caron J, Lhermitte M. High performance liquid chromatography assay for amiodarone N-deethylation in microsomes of rat liver. J Chromatogr 1992; 579: 269-276.
27. 27 Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea and Febiger, 1984.
28. 28 Conover WJ, Iman RN. Analysis of covariance using the rank transformation. Biometrics 1982; 38: 715-724.
29. 29 Bethea RM, Duran BS, Bouillon TL. Statistical methods for Engineers and Scientists 2nd edn. New York: Marcel Dekker Ed 1985.
30. 30 Moochhala SM, Loke KH, Das NP. Spectral perturbation of human microsomal cytochrome P 450 by flavonoid binding. Biochem Int 1988; 17: 755-762.
31. 31 Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59: 1025-1030.
32. 32 Edwards DJ, Bellevue Fh 3rd, Woster PM. Identification of 6'-7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metabol Dispos 1996; 24: 1287-1290.
33. 33 Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-1233.
34. 34 Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human. P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol Pharm Bull 1997; 20: 560-564.
35. 35 He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252-269.
36. 36 Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998; 62: PL135-PL142.
37. 37 Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995; 58: 365-373.
38. 38 Wellens HJJ, Brugada H, Abdollah H, Dassen WRI. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984; 69: 120-124.
39. 39 Morady F, DiCarlo LA, Krol RB, et al. Acute and chronic effects of amiodarone on ventricular refractoriness intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986; 7: 148-157.
40. 40 Shenasa M, Denker S, Mahmud R, et al. Effect of amiodarone on conduction and refractoriness of the His-Purkinje system in the human heart. J Am Coll Cardiol 1984; 4: 105-110.
41. 41 Torres V, Tepper D, Flowers D, et al. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol 1986; 7: 142-147.
42. 42 Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol 1984; 6: 531-535.
43. 43 Ikeda T, Nadamanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentration. Am Heart J 1984; 108: 890-898.
44. 44 Staubli M, Bircher J, Galeazzi RL, Remund H, Stunder H. Serum concentrations of amiodarone during long term therapy: relation to dose, efficacy and toxicity. Eur J Clin Pharmacol 1983; 24: 485-494.
45. 45 Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984; 101: 462-469.